Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.54 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.53 |
| ▸ | IGF1R | P08069 | 8/20 | 0.52 |
| ▸ | CDK2 | P24941 | 5/20 | 0.49 |
| ▸ | CDK4 | P11802 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 4/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.48 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.45 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.45 |
| ▸ | ITK | Q08881 | 2/20 | 0.45 |
| ▸ | SYK | P43405 | 2/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | PLK4 | O00444 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3271859 | 0.81 | IGF1R (0.65) | GSK3BIGF1RCDK2CDK4CDK1 | |
| SCHEMBL3270705 | 0.78 | IGF1R (0.67) | GSK3BIGF1RCDK2CDK4CDK1 | |
| SCHEMBL6068404 | 0.77 | IGF1R (0.64) | GSK3BIGF1RCDK2CDK4CDK1 | |
| SCHEMBL12519502 | 0.75 | EGFR (0.62) | CHEK1NTRK2ITKSYKJAK2 | |
| SCHEMBL21881992 | 0.75 | PTPN11 (0.71) | PTPN11SYKAKT1 | |
| SCHEMBL3269913 | 0.73 | GSK3B (0.69) | GSK3BIGF1RCDK2CDK4CDK1 | |
| SCHEMBL4114769 | 0.73 | SYK (0.59) | GSK3BIGF1RCDK2CDK4CDK1 | |
| SCHEMBL7041264 | 0.73 | PTPN11 (0.68) | PTPN11 | |
| SCHEMBL29691832 | 0.72 | PTPN11 (0.67) | PTPN11 | |
| SCHEMBL3270728 | 0.72 | SYK (0.52) | GSK3BIGF1RCDK2CDK4CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1278735-B1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRIMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2010-06-30 | — | — | EP | disclosed |
| US-7067522-B2 | 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2006-06-27 | — | — | US | disclosed |
| US-20050090515-A1 | 2,4,DI (hetero-) arylamino (-oxy) -5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB | 2005-04-28 | — | — | US | disclosed |
| US-6838464-B2 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents | ASTRAZENECA AB (SE) | 2005-01-04 | — | — | US | disclosed |
| US-20030181474-A1 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2003-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181474-A1 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents | CDK2, CCNI, CDK1 | GSK3B 572/4885PTPN11 1061/4885IGF1R 967/4885 |
| US-20050090515-A1 | 2,4,DI (hetero-) arylamino (-oxy) -5-substituted pyrimidines as antineoplastic agents | CDK2, CDK4, CCNI | GSK3B 568/4885PTPN11 1165/4885IGF1R 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.